{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:18:12Z","timestamp":1787887092433,"version":"build-2784847793"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optimal treatment for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma remains unclear due to limited head-to-head comparisons among chemotherapy and chemoradiation regimens. This network meta-analysis aimed to determine the relative efficacy of available multimodality treatment regimens in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, EMBASE, Scopus, Web of Science, and CENTRAL were searched till September 20, 2024. Phase 3 randomized trials evaluating perioperative\/neoadjuvant systemic therapy\u2005\u00b1\u2005radiation in resectable gastric\/GEJ adenocarcinoma were included. Primary outcomes were disease-free survival (DFS) and overall survival (OS). Frequentist network meta-analysis was conducted to compare hazard ratios (HRs) and 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen trials (8072 patients) were analyzed. pFLOT (perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel) ranked highest for DFS in the overall population (P-score 91%), achieving significant improvements compared to surgery alone (HR 0.48, 95% CI, 0.38-0.60) and nCROSS (neoadjuvant paclitaxel, carboplatin, and radiotherapy) (0.67, 0.56-0.81). For OS, nPLF\u2005+\u2005nCRT(EP) (neoadjuvant cisplatin, leucovorin, and fluorouracil for induction, followed by etoposide, cisplatin, and radiotherapy) (P-score 90%) and pFLOT (P-score 87%) were the top regimens. pFLOT significantly outperformed surgery alone (0.57, 0.45-0.72) and nCROSS (0.73, 0.60-0.89). Based on the limited data available, adding neoadjuvant chemoradiation to pFLOT provided no additional OS (1.14, 0.76-1.72) or DFS (1.22, 0.83-1.82) benefit. Similarly, adding pembrolizumab to perioperative chemotherapy (cisplatin and fluorouracil\/capecitabine) was not superior to pFLOT (DFS: 1.10, 0.71-1.69; OS: 1.09, 0.69-1.72).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>pFLOT demonstrated superior efficacy in resectable gastric\/GEJ adenocarcinoma, outperforming surgery alone, nCROSS, and alternative perioperative regimens. The additive role of immunotherapy requires further investigation to optimize patient selection and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf157","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T09:43:41Z","timestamp":1747993421000},"source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2429-515X","authenticated-orcid":false,"given":"Muhammad Umair","family":"Anjum","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Arsalan Ahmed","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman Ayub","family":"Jajja","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammad","family":"Raina","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Canyon Vista Medical Center, Midwestern University , Sierra Vista, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umar","family":"Afzal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwer Sufyan","family":"Faisal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ziauddin Medical University , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Segovia","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-5833","authenticated-orcid":false,"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry H","family":"Yoon","sequence":"additional","affiliation":[{"name":"Division of Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Luiz Serrano","family":"Uson Junior","sequence":"additional","affiliation":[{"name":"Center for Personalized Medicine, Hospital Israelita Albert Einstein , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Starr","sequence":"additional","affiliation":[{"name":"Division of Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Jacksonville, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4653-4537","authenticated-orcid":false,"given":"Tanios S","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz Bin","family":"Riaz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6931-242X","authenticated-orcid":false,"given":"Mohamad Bassam","family":"Sonbol","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2025080409565104400_CIT0001","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025080409565104400_CIT0002","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025080409565104400_CIT0003","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"key":"2025080409565104400_CIT0004","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"2025080409565104400_CIT0005","author":"National Comprehensive Cancer Network"},{"key":"2025080409565104400_CIT0006","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"2025080409565104400_CIT0007","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025080409565104400_CIT0008","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"2025080409565104400_CIT0009","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/nejmoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"2025080409565104400_CIT0010","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/s1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025080409565104400_CIT0011","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025080409565104400_CIT0012","author":"Anjum"},{"key":"2025080409565104400_CIT0013","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2025080409565104400_CIT0014","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025080409565104400_CIT0015","year":"2024"},{"key":"2025080409565104400_CIT0016","year":"2024"},{"key":"2025080409565104400_CIT0017","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2025080409565104400_CIT0018","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"2025080409565104400_CIT0019","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2025080409565104400_CIT0020","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","article-title":"A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma","volume":"80","author":"Riaz","year":"2021","journal-title":"Eur Urol"},{"key":"2025080409565104400_CIT0021","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025080409565104400_CIT0022","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"key":"2025080409565104400_CIT0023","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"2025080409565104400_CIT0024","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025080409565104400_CIT0025","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/nejmoa2405195","article-title":"Preoperative chemoradiotherapy for resectable gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"key":"2025080409565104400_CIT0026","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence","volume":"108","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2025080409565104400_CIT0027","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"2025080409565104400_CIT0028","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/jco.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled cross trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025080409565104400_CIT0029","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025080409565104400_CIT0030","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(05)70288-6","article-title":"Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial","volume":"6","author":"Burmeister","year":"2005","journal-title":"Lancet Oncol"},{"key":"2025080409565104400_CIT0031","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial","volume":"81","author":"Stahl","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025080409565104400_CIT0032","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025080409565104400_CIT0033","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(17)30447-3","article-title":"Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial","volume":"18","author":"Alderson","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025080409565104400_CIT0034","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/s0140-6736(02)08651-8","article-title":"Surgical resection with or without preoperative chemotherapy in oesophageal cancer:a randomised controlled trial","volume":"359","author":"Medical Research Council Oesophageal Cancer Working Party","year":"2002","journal-title":"Lancet"},{"key":"2025080409565104400_CIT0035","doi-asserted-by":"publisher","first-page":"S1520","DOI":"10.1016\/j.annonc.2023.10.265","article-title":"129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): Interim results of the global, phase III MATTERHORN study","volume":"34","author":"Oh","year":"2023","journal-title":"Ann Oncol"},{"key":"2025080409565104400_CIT0036","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1200\/jco.2024.42.16_suppl.4000","article-title":"A phase II\/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174)","volume":"42","author":"Eads","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025080409565104400_CIT0037","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025080409565104400_CIT0038","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annonc.2021.02.004","article-title":"Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy","volume":"32","author":"Smyth","year":"2021","journal-title":"Ann Oncol"},{"key":"2025080409565104400_CIT0039","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1200\/JCO.23.01982","article-title":"Neoadjuvant immunotherapy in gastroesophageal cancer: a promising early signal","volume":"42","author":"Zhu","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf157\/63738186\/oyaf157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyaf157\/63738186\/oyaf157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyaf157\/63738186\/oyaf157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T13:57:03Z","timestamp":1754315823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf157\/8198426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf157","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8]]},"article-number":"oyaf157"}}